Profilo
James M.
DeTore is currently Chief Financial Officer at CG Oncology, Inc. since 2026.
Former positions include Chief Financial Officer at Neurogastrx, Inc. from 2021 to 2025; Chief Financial Officer & Treasurer at Proteostasis Therapeutics, Inc. from 2016 to 2017; Chief Financial Officer & Treasurer at Genetix Biotherapeutics, Inc. from 2014 to 2016; Vice President-Finance & Administration at Ironwood Pharmaceuticals, Inc. from 2012 to 2014; Controller at Microbia, Inc. from 2003 to 2006; Principal at Genzyme Corp.; and Principal at Data General Corp.
Education includes undergraduate and MBAistration degrees from Northeastern University.
Posizioni attive di James DeTore
| Società | Posizione | Inizio |
|---|---|---|
| CG ONCOLOGY, INC. | Direttore Finanziario/CFO | 17/11/2025 |
Precedenti posizioni note di James DeTore
| Società | Posizione | Fine |
|---|---|---|
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops transformative therapies for gastrointestinal disorders | Direttore Finanziario/CFO | 01/06/2025 |
| PROTEOSTASIS THERAPEUTICS, INC. | Direttore Finanziario/CFO | 10/02/2017 |
| GENETIX BIOTHERAPEUTICS, INC. | Direttore Finanziario/CFO | 01/03/2016 |
| IRONWOOD PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 17/06/2011 |
Microbia, Inc.
Microbia, Inc. Pharmaceuticals: MajorHealth Technology Develops microbial manufacturing technologies | Comptroller/Controller/Auditor | 01/01/2006 |
Formazione di James DeTore
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 9 |
|---|---|
Data General Corp.
Data General Corp. Computer PeripheralsElectronic Technology Designs and makes open computer systems including servers and mass storage products | Electronic Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets gastrointestinal products | Health Technology |
Microbia, Inc.
Microbia, Inc. Pharmaceuticals: MajorHealth Technology Develops microbial manufacturing technologies | Health Technology |
bluebird bio, Inc.
bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Develops disease-modifying therapeutics for orphan and neurodegenerative diseases | Health Technology |
CG Oncology, Inc.
CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops transformative therapies for gastrointestinal disorders | Health Technology |
















